Show Summary Details
Page of

Tumours of the skin 

Tumours of the skin

Tumours of the skin

Edel O’Toole



Basal cell carcinoma—trial findings regarding therapies.

Squamous cell carcinoma—update on genetics.

Malignant melanoma—genetics and treatment updated to include recent clinical trial data.

Updated on 28 Nov 2013. The previous version of this content can be found here.
Page of

PRINTED FROM OXFORD MEDICINE ONLINE ( © Oxford University Press, 2015. All Rights Reserved. Under the terms of the licence agreement, an individual user may print out a PDF of a single chapter of a title in Oxford Medicine Online for personal use (for details see Privacy Policy).

date: 28 April 2017

A wide range of tumours, both benign and malignant, are found in skin. Benign skin lesions such as seborrhoeic keratoses and skin tags are often just a cosmetic nuisance, but some benign skin lesions can be a component of diseases with serious medical consequences, e.g. neurofibromatosis or LEOPARD syndrome.

Exposure to ultraviolet light (UVL) is a major factor leading to the development of both benign lesions, e.g. melanocytic naevi, and most skin cancers. Changes in dress style, increased travel abroad, use of sun tanning salons (sunbeds), and the depletion of the ozone layer have all contributed to increased exposure to UVL.

Skin cancer is the most common human cancer and its incidence continues to increase. It most commonly affects older, fair-skinned individuals who have had either acute intermittent exposure to UVL or chronic UVL exposure. Organ transplant recipients have a 200-fold increased risk of squamous cell carcinoma. About 2% of patients who develop skin cancer have a genetic predisposition, e.g. Gorlin’s syndrome in basal cell carcinoma (BCC) and familial melanoma syndromes in malignant melanoma. Mutations in the PTCH gene cause Gorlin’s syndrome, and loss of heterozygosity at that locus is also present in most sporadic BCC.

Nonmelanoma skin cancer is rarely fatal, but can cause a lot of morbidity. Malignant melanoma is a deadly skin cancer which is the 2nd most common cancer (excluding nonmelanoma skin cancer) in young women. Over the last 20 years, its incidence has been increasing faster than any other cancer, with an approximate doubling of rates every 10 years in countries with largely white populations. Early detection and excision of melanoma is the best way to reduce mortality, as there is no curative treatment for metastatic malignant melanoma.

Access to the complete content on Oxford Medicine Online requires a subscription or purchase. Public users are able to search the site and view the abstracts for each book and chapter without a subscription.

Please subscribe or login to access full text content.

If you have purchased a print title that contains an access token, please see the token for information about how to register your code.

For questions on access or troubleshooting, please check our FAQs, and if you can't find the answer there, please contact us.